Publicaciones en colaboración con investigadores/as de Consejo Superior de Investigaciones Científicas (21)

2024

  1. Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells

    British Journal of Haematology, Vol. 205, Núm. 4, pp. 1346-1355

2023

  1. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Nature Communications, Vol. 14, Núm. 1

2021

  1. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

    Leukemia, Vol. 35, Núm. 8, pp. 2358-2370

2020

  1. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

    Blood Cancer Journal, Vol. 10, Núm. 10

2014

  1. Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: New criteria for differential diagnosis and risk stratification

    Leukemia, Vol. 28, Núm. 1, pp. 166-173

2013

  1. HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma

    Blood, Vol. 122, Núm. 8, pp. 1448-1454

2012

  1. The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation

    Haematologica, Vol. 97, Núm. 9, pp. 1329-1337

2010

  1. Immunomodulatory effect of 5-azacytidine (5-azaC): Potential role in the transplantation setting

    Blood, Vol. 115, Núm. 1, pp. 107-121

2009

  1. A Prolonged Therapy Improves Quality of Response, and CR Associated with Superior Outcomes, with VMP

    CLINICAL LYMPHOMA & MYELOMA

  2. Bortezomib and Melphalan as Part of VMP Are Associated with Similar Hematologic Toxicity to MP Alone

    CLINICAL LYMPHOMA & MYELOMA

  3. DNA DSBs Induction by Zalypsis, a Novel Marine Compound, Results in Potent Antimyeloma Activity

    CLINICAL LYMPHOMA & MYELOMA

  4. Erythropoiesis-Stimulating Agents: No Impact on Long-Term Outcome in MM Patients in the VISTA Trial

    CLINICAL LYMPHOMA & MYELOMA

  5. Flow Cytometry Remission Is the Most Relevant Prognostic Factor for MM Patients Who Undergo ASCT

    CLINICAL LYMPHOMA & MYELOMA

  6. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia

    Blood, Vol. 114, Núm. 1, pp. 148-152

  7. New drugs and novel therapeutic principles in multiple myeloma

    EJC SUPPLEMENTS

  8. Peripheral Neuropathy with VMP Resolves in the Majority of Patients and Shows a Rate Plateau

    CLINICAL LYMPHOMA & MYELOMA

  9. Tyrosine Kinase Inhibition in MM? Efficacy of the Combination of Dasatinib/Bortezomib/Dexamethasone

    CLINICAL LYMPHOMA & MYELOMA

  10. VMP Results in Fewer Bone Events and Greater ALP Increases Versus MP in the VISTA Study in Front-Line MM

    CLINICAL LYMPHOMA & MYELOMA

  11. VMP in Renally Impaired Newly Diagnosed MM Patients: Cohort Analysis of the VISTA Study

    CLINICAL LYMPHOMA & MYELOMA

2008

  1. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: Efficacy and safety in patients with renal function impairment

    Clinical Lymphoma and Myeloma, Vol. 8, Núm. 6, pp. 352-355